Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Capital Expenditures (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Capital Expenditures for 12 consecutive years, with $32000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 63.64% year-over-year to $32000.0, compared with a TTM value of $58000.0 through Dec 2025, down 89.57%, and an annual FY2025 reading of $58000.0, down 89.57% over the prior year.
  • Capital Expenditures was $32000.0 for Q4 2025 at Catalyst Pharmaceuticals, up from $26000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $911000.0 in Q1 2021 and bottomed at $1000.0 in Q2 2021.
  • Average Capital Expenditures over 4 years is $143538.5, with a median of $68000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures surged 304.69% in 2024, then tumbled 63.64% in 2025.
  • Year by year, Capital Expenditures stood at $41000.0 in 2021, then surged by 126.83% to $93000.0 in 2023, then dropped by 5.38% to $88000.0 in 2024, then crashed by 63.64% to $32000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CPRX at $32000.0 in Q4 2025, $26000.0 in Q2 2025, and $88000.0 in Q4 2024.